RPS Announces Partnership with Leading Korean Biopharmaceutical Giant, Celltrion

Share Article

Agreement will focus on matching groundbreaking diagnostic and therapeutic technologies

Sarasota, Fla.-based, Rapid Pathogen Screening (RPS®) – a leading developer and manufacturer of rapid cost-effective point-of-care diagnostic tests – announced its partnership with Korean biopharmaceutical pioneer, Celltrion, Inc., (KDQ:068270) at a New York City press conference today.

Originally introduced by the Center for Disease Control (CDC), the momentous partnership combines – for the first time – highly sensitive diagnostic technology with highly effective therapeutic technology to benefit global health.

“We are thrilled to partner with Celltrion to bring critical tools to healthcare professionals to more successfully identify, overcome and prevent specific diseases,” said Tom Orsini, president and CEO of RPS. “Through the development of these technologies, our partnership will change the way the global healthcare system operates. It’s about giving patients better care at a lower cost.”

Celltrion, approximately a 3.6 billion USD (March 31, 2011) publicly traded Korean biopharmaceutical brand, became interested in a partnership with RPS after evaluating the novel and versatile technology platform found in the RPS Adeno Detector™. This point-of-care test provides a rapid and accurate diagnosis of viral conjunctivitis (commonly known as pink eye), enabling physicians to treat patients more effectively and appropriately. In the months to come, the revolutionary science behind the tests will be utilized to produce further point-of-care diagnostics for other well-known pathogens.

About RPS
Founded in 2004, Rapid Pathogen Screening, Inc. (RPS) is a leading developer, manufacturer and marketer of rapid easy-to-use, point-of-care diagnostic tests. The company’s revolutionary, patented Direct Sampling Micro-Filtration (DSMF) technology and patent-pending Direct Multi-Planar Chromafiltography (DMC) technology allow for the current and future development of tests to confirm patients with infectious diseases and agents, inflammatory conditions, and asymptomatic exposure to chemical warfare and bio-terrorism agents. RPS tests have superior sensitivity and specificity and can be easily performed by a clinician’s staff without extensive training or additional equipment.

For additional information or to schedule an interview, contact:
Danielle Hagen, RPS, 202.365.6112

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website